about
Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis casesEfficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.Clinical features of childhood granulomatosis with polyangiitis (wegener's granulomatosis)EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation.An international registry on autoinflammatory diseases: the Eurofever experience.Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey.Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaborationTakayasu arteritis in childhood: retrospective experience from a tertiary referral centre in the United Kingdom.PRINTO/PRES international website for families of children with rheumatic diseases: www.pediatric-rheumatology.printo.it.Polyclonal, newly derived T cells with low expression of inhibitory molecule PD-1 in tonsils define the phenotype of lymphocytes in children with Periodic Fever, Aphtous Stomatitis, Pharyngitis and Adenitis (PFAPA) syndrome.Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa.Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administrationThe PRINTO criteria for clinically inactive disease in juvenile dermatomyositisConsensus-based recommendations for the management of juvenile dermatomyositis.Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.Development of the autoinflammatory disease damage index (ADDI).Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS).677TT genotype is associated with elevated risk of methotrexate (MTX) toxicity in juvenile idiopathic arthritis: treatment outcome, erythrocyte concentrations of MTX and folates, and MTHFR polymorphisms.Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis.Biologic therapy in primary systemic vasculitis of the young.An improved high-performance liquid chromatography method for quantification of methotrexate polyglutamates in red blood cells of children with juvenile idiopathic arthritis.Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients.European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative.Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: The pediatric rheumatology international trials organization multinational quality of life cohort studyThe Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the definition of improveJuvenile polyarteritis: Results of a multicenter survey of 110 childrenA randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate
P50
Q30795448-3505E239-F163-4E4B-8093-0EE5DA17561DQ33659233-37859735-F104-4699-B92A-A838383D7B69Q33696589-3DD5B583-DB9D-42C0-A162-8399FCC1A92FQ34109962-240DBC54-B42E-4C51-9027-231AE2E2A7BCQ34257724-ABF51F9E-0B0B-4353-9F56-1320BE71AAD3Q34461699-558D6FAD-9F9D-498B-8B28-53E52792C0D2Q35102471-CAC16EA0-FE90-4373-84A5-0855E86240B9Q35354592-2ACCA242-5A8E-4CBB-BBE8-9B793BBEFD53Q35555785-3A5B5246-EF38-4CA5-A220-0D50E0EC0773Q35556285-192A49A2-BEB4-4F92-808B-335987E8FD60Q35590334-1B2D2966-2189-49D7-ABF2-B7C77B40F2BDQ37006464-AE61A844-4B1B-4942-B866-56C6302F0D45Q37293030-4A07FD78-D5AF-4DFF-9E7E-BBEEF3577189Q37617000-35A9AAAE-FB52-4271-9932-DCD9C5BC9268Q38374642-1FF80F2C-40AF-4D64-AC45-43DD142A05D9Q38997969-BFA6B285-10EA-464F-ACC9-4A7D9B49BD2CQ39530208-06A76638-BCF8-4468-8D02-D60B2BDE05E9Q42994494-CB12C5F6-84E6-4F55-ABC7-BEC7AE7179D3Q45083379-31925300-19FD-4144-8718-CC7F0B67EE77Q45964920-17BCB955-9FF5-4FC0-B10C-6AC3315DBF55Q46074030-5AF103A8-199E-4D23-A028-575A462B6AF2Q46966710-45B8A3AF-2747-4006-8197-D2201B11E0ABQ52601030-85F2EB1C-8AA4-4419-8A8A-DA587A30489AQ57330812-055C19CC-BE6D-4D98-B3DC-822D72139724Q57330884-DAA3CF5F-8D36-4712-BF2B-68C2EEAC6613Q58429172-CC3BA79A-299E-4E0C-81C4-2D04FD3E96AFQ80330583-CC43C4BF-DD26-4951-85F7-EB636AC8E3A0
P50
description
pediatrička, revmatoložka
@cs
researcher ORCID ID = 0000-0001-8375-661X
@en
wetenschapper
@nl
name
P Dolezalova
@ast
P Dolezalova
@nl
Pavla Doležalová
@cs
Pavla Doležalová
@en
Pavla Doležalová
@es
type
label
P Dolezalova
@ast
P Dolezalova
@nl
Pavla Doležalová
@cs
Pavla Doležalová
@en
Pavla Doležalová
@es
prefLabel
P Dolezalova
@ast
P Dolezalova
@nl
Pavla Doležalová
@cs
Pavla Doležalová
@en
Pavla Doležalová
@es
P106
P214
P1153
6603422138
P19
P21
P214
P31
P496
0000-0001-8375-661X
P569
1960-06-01T00:00:00Z
P691
nlk20040158529
P735
P7859
viaf-84864812